Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

First Results from PANGAEA2.0 EVOLUTION: State of the Art Management of Patients with Secondary Progressive Multiple Sclerosis (SPMS) or at Risk for SPMS to Identify Key Parameters in Daily Clinical Practice for an Early and Unified Diagnosis
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-021

PANGAEA2.0 EVOLUTION aims to document a broad set of disability parameters and patient reported outcomes in patients with relapsing-remitting multiple sclerosis (RRMS), RRMS at risk for SPMS and SPMS to:

  • identify key characteristics marking the transition phase from RRMS to SPMS
  • compare current diagnostic criteria with a novel digital tool (MSProDiscuss)
While most MS patients are diagnosed with RRMS, the majority converts to SPMS within 20 years. However, both diagnosis of SPMS and identification of the transition phase remain challenging, as there are no reliable diagnostic tests or biomarkers available.

PANGAEA2.0 EVOLUTION is part of the ongoing non-interventional real-world study PANGAEA2.0 with approximately 2,500 RRMS patients. In the EVOLUTION arms additionally 1,000 patients diagnosed with SPMS or classified as at risk for SPMS based on physician’s evaluation are prospectively followed independent of treatment for up to 2 years. Observation parameters collected at 6-month intervals include a broad set of routine clinical parameters as well as patient and physician reported outcomes.
Baseline data and first follow-up insights reveal patients at risk for SPMS are older with longer disease duration and higher disease burden as assessed by cognitive deficits (SDMT) and fatigue (FSMC) when compared to RRMS. By April 2020 we will show first real world data comparing profiles of 300 patients with different progression states to SPMS including an analysis of physician’s evaluation and the algorithm based MsProDiscuss.
PANGAEA2.0 EVOLUTION allows characterization of different progressive patient profiles in a real world setting. Identifying key symptoms associated with the underlying progression helps to define a more accurate and unified diagnosis for progression and SPMS and subsequently a better long-term outcome for these patients.
Authors/Disclosures

PRESENTER 		No disclosure on file
Tjalf Ziemssen, MD, FÂ鶹´«Ã½Ó³»­ (University Clinic Dresden) Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.